

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/11542

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl ⁷ A61K31/22, A61P13/12		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl ⁷ A61K31/22, A61P13/12		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), REGISTRY (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 191735 A1 (NIPPON ZOKI PHARMACEUTICAL CO., LTD.), 20 August, 1986 (20.08.86), Particularly, page 21, lines 4 to 9 & JP 61-183259 A Particularly, page 26, lines 4 to 7	1, 2, 4, 5
Y	Shigeaki HINOHARA·Masakazu ABE, "Today's Therapy 1997 Nenban (pocket edition)", 2nd print, Kabushiki Kaisha Igakushoin, 1997, page 463	1, 2, 4, 5
A	Takuji NARUKIYO·Yasushi ASANO, "Bessatsu·Igaku no Ayumi, Jin Shikkan-state of arts", Ishiyaku Pub., Inc., 1992, pages 224 to 225	1-5
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 09 October, 2003 (09.10.03)		Date of mailing of the international search report 28 October, 2003 (28.10.03)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1998)

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/11542

<Subject of search>

The inventions as claimed in claims 1 to 5 relate to use of the drug according to the invention for kidney failure. Discussion on the statement of the description of the present case indicates that the usefulness of the drug according to the invention is proved exclusively by the experimental data showing the inhibition of an increase in blood creatinine level accompanying the progress of kidney failure in rats suffering from adenine-induced kidney failure. Since there are various differences in pathological conditions between acute kidney failure and chronic kidney failure, it appears that model animals of these diseases are to be constructed by different methods. The above-described model rats correspond to models of chronic kidney failure (see, if necessary, 'separate volume Igakuno Ayumi Jinshikkan - state of art' in "C. DOCUMENT CONSIDERED TO BE RELEVANT" in the previous sheet). Accordingly, the experimental data as described above show the inhibition of the progress of kidney failure in chronic kidney failure with the use of experimental models of chronic kidney failure and, therefore, cannot be considered as showing the usefulness of the drug according to the invention in treating or preventing acute kidney failure.

Such being the case, the search was made on the part that is disclosed in the description and supported thereby, namely, inhibition of the progress of kidney failure in chronic kidney failure.

Based on the statement in the description, it appears that the structure -C(O)-N-C(O)- of the oxaluric acid derivative represented by (I) given in claims is a clerical error for -C(O)-NH-C(O)-.

Such being the case, the search was made on compounds having the structure -C(O)-NH-C(O)-.